201541-36-8

Basic information

• Product Name: 1,2,3,4-tetrahydro-2,2-diMethyl-7-nitroquinoline
• Synonyms: 1,2,3,4-tetrahydro-2,2-diMethyl-7-nitroquinoline
• CAS NO: 201541-36-8
• Molecular Formula: C11H14N2O2
• Molecular Weight: 206.24106
• Mol File: 201541-36-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2,3,4-tetrahydro-2,2-diMethyl-7-nitroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-tetrahydro-2,2-diMethyl-7-nitroquinoline(201541-36-8)
• EPA Substance Registry System: 1,2,3,4-tetrahydro-2,2-diMethyl-7-nitroquinoline(201541-36-8)

Safety Data

• Hazardous Substances Data: 201541-36-8(Hazardous Substances Data)

Usage

Chemical structure

Nitroquinoline derivative with two methyl groups attached to the second carbon atom

Physical state

Likely a solid at room temperature (common for many organic compounds)

Appearance

Unknown, but may be a yellow or orange solid based on similar compounds

Solubility

Likely soluble in organic solvents such as ethanol, methanol, or acetone

Fluorescent properties

Used as a fluorescent dye in biological and chemical research

Analytical techniques

Suitable for fluorescence microscopy and flow cytometry

Potential therapeutic applications

Studied for use in cancer research

Material development

May have applications in the development of new materials and technologies due to its unique chemical properties

Stability

Unknown, but may be sensitive to light, heat, or moisture (common for many organic compounds)

Upstream product

• 20364-30-1 2,2-dimethyl-1,2,3,4-tetrahydroquinoline 
• 132588-91-1 1,2,3,4-tetrahydro-2,2-dimethylquinolin-4-one 
• 179898-87-4 1-tert-butoxycarbonyl-1,2,3,4-tetrahydro-2,2-dimethyl-4-quinolinone 
• 14465-61-3 2,2-dimethyl-1,2-dihydroquinoline 
• 7471-09-2 3-methyl-3-phenylamino-1-butyne 

Downstream Products

• 179899-22-0 7-amino-1,2,3,4-tetrahydro-2,2-dimethylquinoline 

Relevant articles and documents

Androgen receptor modulator compounds and methods

Non-steroidal compounds that are high affinity, high selectivity modulators for androgen receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring androgen receptor agonist, partial agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the androgen receptor modulator compounds.

Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2- dihydropyridono[5,6-g]quinolines

A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR- mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure - activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.